Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital |
---|---|
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00768144 |
The purpose of this study is to determine the effectiveness of sunitinib on participants with ovarian, fallopian tube or peritoneal cancer. Sunitinib is a newly discovered drug that may stop cancer cells from growing by blocking the blood supply to the tumor.
Condition | Intervention | Phase |
---|---|---|
Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer |
Drug: Sunitinib |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma |
Estimated Enrollment: | 35 |
Study Start Date: | September 2008 |
Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Susana M Campos, MD | 617-632-5269 | |
Contact: Christin Whalen, RN | 617-632-7738 |
United States, Massachusetts | |
Dana-Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Principal Investigator: Susana M. Campos, MD | |
Beth-Israel Deaconess Medical Center | Recruiting |
Boston, Massachusetts, United States, 02215 | |
Principal Investigator: Susan Schumer, MD | |
Massachusetts General Hospital | Not yet recruiting |
Boston, Massachusetts, United States, 02214 | |
Principal Investigator: Richard T. Penson, MD |
Principal Investigator: | Susana M. Campos, MD | Dana-Farber Cancer Institute |
Responsible Party: | Dana-Farber Cancer Institute ( Susana Campos, MD ) |
Study ID Numbers: | 08-056 |
Study First Received: | September 29, 2008 |
Last Updated: | October 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00768144 |
Health Authority: | United States: Institutional Review Board |
Sutent sunitinib |
Ovarian cancer Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female Endocrine System Diseases Urogenital Neoplasms Ovarian Diseases Fallopian Tube Neoplasms |
Recurrence Carcinoma Fallopian Tube Diseases Genital Diseases, Female Sunitinib Endocrinopathy Fallopian tube cancer Endocrine Gland Neoplasms |
Neoplasms Neoplasms by Site Antineoplastic Agents Growth Substances Therapeutic Uses Physiological Effects of Drugs |
Growth Inhibitors Angiogenesis Modulating Agents Angiogenesis Inhibitors Pharmacologic Actions Adnexal Diseases |